Research and AI: DigitalKin & CCI join forces
Philippe Valentin, President of the CCI Lyon Metropole Saint-Etienne Roanne and Emmanuel Théry, CEO and Co-founder of DigitalKin illustrate in this interview the challenge ofAI in business through a concrete case: that of scientific research, where the use of Kins R&D By 10 the time required for a Literature review, thus freeing up teams for missions with high added value.
What you had to remember...
In this rapidly changing ecosystem, CIC has chosen to invest, via CCI Capital Croissance, in DigitalKin, which redefines the standards of artificial intelligence applied to demanding environments such as scientific research, particularly in health, where reliability and transparency are categorical imperatives.
Thanks to his platform, it allows businesses to create and configure autonomous AI agents, called Kins, capable of carrying out complex tasks while guaranteeing traceability, human control and reliability of results. This agentic approach, based on a multi-agent architecture unlike traditional “black boxes”, offers complete visibility on how AI works, which is then defined as:
A configurable and controllable AI : each Kin can be configured to meet specific business protocols, such as R&D and Innovation. Professionals precisely define their ontology, rules, rules, policies, methodologies, and decision thresholds, by integrating human validation points to control the quality and conformity of the results.
Traceable and transparent AI : all the actions of a Kin automatically generate detailed reports, making it possible to trace and justify each step of the process. This traceability gives professionals complete control of the execution, with the ability to intervene in real time if necessary.
A responsible and reliable AI : this combination of human control/traceability/validation allows professionals to endorse the results produced by AI. It promotes ethical, safe, and defensible use, aligned with AI governance requirements and regulations like the European AI Act.
“Europe has built its scientific reputation on rigor and evidence. Our autonomous AI agents, Kins, are part of this tradition: they don't just analyze, they execute your protocols, document every decision, and let you validate the results with confidence.
An AI that accelerates discovery without sacrificing method? It is possible, and our R&D departments have everything to gain from it, starting with some pharmaceutical players in Lyon who have already taken the plunge with DigitalKin. ” — Emmanuel Théry, CEO and Co-founder of DigitalKin